Ned Sharpless to continue where Scott Gottlieb left off at FDA
Sharpless pledged to continue the agency's work promoting innovation and competition while tackling problems like vaccine avoidance and marketing of unsafe and unproven health products.
Sharpless pledged to continue the agency's work promoting innovation and competition while tackling problems like vaccine avoidance and marketing of unsafe and unproven health products.
Sharpless, the director of the National Cancer Institute, was reportedly favored by HHS Secretary Alex Azar as outgoing Commissioner Scott Gottlieb's successor.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Gottlieb, who is expected to step down in about a month, leaves behind a unique legacy and will likely be difficult to replace.